Expert Interviews

Unmasking a Hidden Driver of Hypertension: Insights from Dr. Florian Rader
Aldosterone may be the hidden culprit in hard-to-treat hypertension, offering new hope for targeted therapies.
Advertisement
Deepak L. Bhatt, MDHeart Failure | July 2, 2025
Deepak Bhatt, MD, discusses EMPACT-MI findings on empagliflozin’s kidney safety and heart failure benefits after ACS.
Dr. Gareth MatthewsPreventive Cardiology | June 25, 2025
AI-powered cardiac MRI shows how aging impacts heart structure—and reveals hidden risks from common conditions.
Joseph M. Kim, MDAtherosclerotic Disease | June 6, 2025
Black patients face higher amputation risk from PAD due to late CLTI care and limited access to revascularization.
CardioNerdsHeart Failure Congress 2025 | June 5, 2025
ESC 2025: Acoramidis may reduce AF/flutter burden in ATTR-CM, per new ATTRibute-CM trial analysis discussed by CardioNerds.
Holger Eltzschig, MD, PhDPreventive Cardiology | May 27, 2025
BMAL1-HIF2α link explains why AM heart attacks hit harder—new findings may lead to time-based cardioprotective therapies.
Mark GoddardHeart Failure | May 23, 2025
AI-driven ECGs are transforming heart failure care—enabling early detection, cutting costs, and expanding access.
Payal Kohli, MD, FACCHypertension | May 19, 2025
Dr. Payal Kohli dives into new tech and AI reshaping how we diagnose and manage hypertension.
Payal Kohli, MD, FACCHypertension | May 16, 2025
Hypertension isn’t just a part of aging—lifestyle, awareness, and new treatments matter.
CardioNerdsCardioNerds | May 12, 2025
Dr. Daniel Judge discusses how the ATTRibute-CM trial marks a turning point in ATTR cardiomyopathy treatment and research.
CardioNerdsCardioNerds | May 2, 2025
Dr. Dan Judge speaks to The CardioNerds about his interpretation of the primary findings from ATTRibute-CM.
Advertisement
Advertisement
Advertisement